Although Dendreon's (NASDAQOTH: DNDNQ ) performance hasn't met lofty investor expectations, there is still real reason to be excited. In this video, Motley Fool health care analyst David Williamson discusses Dendreon's potentially revolutionary prostate cancer vaccine, Provenge, and how it can capitalize on the enormous prostate cancer market.
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as Provenge became a lightning rod of debate. But where does that leave investors? David answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.